AMCP Nexus 2023 to Showcase Regulatory, Policy Updates and Evolving Managed Care Strategies

AMCP Nexus 2023, the annual fall meeting of the Academy of Managed Care Pharmacy will convene in Orlando, Florida. The conference will run October 16-19.

Image credit: THANANIT - stock.adobe.com

The meeting will kick off with a preconference session on the fundamentals of the Inflation Reduction Act (IRA) and how it will impact pharmaceutical manufacturers, payers, and patients. The program will also highlight some of the developments and implications of the Medicare Drug Price Negotiation Program.

The first batch of education sessions will cover an update on federal legislative and regulatory actions and how artificial intelligence can help managed care plans better utilize pharmacy data. A spotlight session will address obstacles preventing the end of the HIV epidemic, including how social determinants of health create disparities in populations of people with HIV.

Aimee Tharaldson, PharmD, clinical program principal, emerging therapeutics, Evernorth, will be presenting her usual updated overview of specialty pharmaceuticals in development that are expected to receive FDA approval in the next 12 months, as well as the likely effect these new medicines will have on the managed care market.

Several presentation on Tuesday, October 17, will focus on understanding the regulatory landscape and considerations for manage care practices, including:

• How medically integrated dispensing services can create value for payers and providers
• A panel discussion on the outlook of managed care pharmacy practice, including budgetary challenges and health policy hurdles, from an administrator perspective
• An evaluation on payer coverage for digital therapeutics, featuring real-world examples and lessons learned
• An overview of legislation on pharmacy benefit managers and health care reform
• Marketplace trends and regulatory considerations in the biosimilar space

Sessions will also cover treatment enhancements in the Alzheimer disease space, identifying potential gene therapeutics using pharmaceutical claims data, navigating health disparities in obesity for managed care pharmacists, and practical implications of the 340B program for managed care pharmacists.

Furthermore, attendees will be able to check out a podium session highlighting award-winning research on the manages care pharmacy research agenda. The session will feature presentations on:

• Identification and management of duplicate therapy involving therapies for diabetes and weight loss
• Racial and class disparities related to specialty drug use within employer-sponsored health insurance plans
• A review of evidence trends in the Institute for Clinical and Economic Review’s unsupported price increase reports
• An evaluation on the impact of the IRA’s out-of-pocket spending cap on Medicare Part D beneficiaries

The event closes with a deep dive into the recently approved and highly anticipated oncology therapies, including differentiation between mechanisms of action, indications, safety, and efficacy of newly approved and emerging oncology specialty medications.